AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + Pomalidomide
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Refractory Multiple Myeloma
Conditions
Relapsed Refractory Multiple Myeloma
Trial Timeline
Feb 23, 2026 → Jul 29, 2030
NCT ID
NCT07391657About AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + Pomalidomide
AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + Pomalidomide is a phase 3 stage product being developed by AstraZeneca for Relapsed Refractory Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07391657. Target conditions include Relapsed Refractory Multiple Myeloma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Refractory Multiple Myeloma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07391657 | Phase 3 | Recruiting |
Competing Products
20 competing products in Relapsed Refractory Multiple Myeloma